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5. Marks DJ, Dheda K, Dawson R, Ainslie G, Miller RF. AdverseDear Editor,
Saraceni et al.1 report the results of the THRio observational
cohort, which showed an 89% increased risk of mortality when
antiretroviral  therapy (ART) was  delayed (more than 60 days
and  less 365 days after tuberculosis (TB) treatment) during
HIV-associated TB. However, the median CD4 count at TB
diagnosis  in this cohort was  150 cells/L, a fact that may  com-
promise  the generalization and interpretation of the study
results.  On the other hand, the investigators provide further
support  to WHO  guidelines, which recommend that all HIV-
infected  individuals with active TB (regardless of CD4 cell
count)  should receive ART as soon as possible, generally within
2–8  weeks.2 Recently, Mﬁnanga et al.3 showed that delaying
ART  prescription for at least six months (TB treatment) was
not  inferior in terms of TB treatment outcome and overall
survival, when compared to early ART within two weeks of
starting  TB treatment in patients with CD4 cell counts more
than  220 cells/L. Additionally, the early ART arm was  associ-
ated  with a non-signiﬁcant increase in TB recurrences.
The treatment of HIV-associated TB remains a daunt-
ing  and challenging task; challenges include excessive pill
burden,  patient compliance, drug interactions, overlapping
treatment toxicities, and emergence of immune reconsti-
tution  disease.4 Moreover, it is estimated that severe drug
adverse  events occurred more  often among HIV-infected TB
patients  compared with uninfected subjects.5 Conversely,
obviating the concomitant TB/HIV therapy, especially in
individuals  with preserved immune function, might simplify
TB  management cases, increasing adherence as well as main-
taining  the same overall survival outcome, as seen in early
DOI of original article: http://dx.doi.org/10.1016/j.bjid.2014.02.004.ART strategy. Therefore, the time is ripe for policy makers
and  scientists to harmonize approach regarding when to start
ART  during TB coinfection.
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